I'm a general practitioner, and I have a patient in their 60s with persistent, moderate lower back pain. They've tried standard NSAIDs with limited relief and are asking about glucosamine supplements based on a friend's recommendation. I'm aware the systematic reviews and meta-analyses on glucosamine for osteoarthritis are mixed at best, but I want to give them a properly informed answer. I'm struggling to reconcile the desire to honor patient preference with the principles of evidence-based medicine when the evidence is so equivocal. How do other clinicians navigate these conversations when the data isn't clear-cut but a patient is eager to try a low-risk supplement?
Data on glucosamine for back pain is pretty thin. If the patient understands that and still wants to try, a brief, monitored trial can be reasonable.
I usually frame it as shared decision making: explain the limited spine-specific evidence, review safety (shellfish allergy, GI upset, rare interactions with anticoagulants), and propose a 6–8 week trial at 1500 mg daily with a clear stop rule and follow-up to reassess.
Personally, I’d still encourage focusing on proven basics first—physical therapy, core strengthening, weight, posture—while offering glucosamine as a low‑risk option for patients who want it. If they start, I’d document baseline pain scores and function, check meds for potential interactions, and ensure they’re using a reputable brand. If no benefit after 6–8 weeks, we move on; if adverse effects pop up, we stop.
I’m wary of nudging patients toward supplements as a first-line fix; the data isn’t great and we should be honest about that. But if they value autonomy and it’s low risk, it’s a reasonable part of a broader plan—not a substitute for exercise, PT, or meds that help them.
Do you routinely discuss quality of evidence with your patient, or is this more a 'try and see' approach? Also, what dose range do you prefer—1500 mg daily split or once? And how do you handle brand quality concerns?
I’ve had a few 60–70-something patients try it. A couple reported small improvements, others felt nothing. The common thread was that it didn’t replace other treatments, just added a little optional layer, with careful monitoring.